Cedars-Sinai investigators led an update of staging guidelines for HPV-positive throat cancer—now more common in the U.S. than cervical cancer, according to the American Cancer Society—that will make treatment of early-stage disease more consistent and appropriate. Their study was published in The Lancet Oncology.